Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
NCT ID: NCT04392297
Last Updated: 2025-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2019-07-01
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Response to Cytomegalovirus
NCT00034437
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates
NCT00677482
Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress
NCT01397058
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
NCT01326273
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
NCT00273143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* identify and characterize immunological disorders in patients with CMV infection complicated by thromboembolism of various localization;
* determine the presence and quantitative content in plasma / serum and neutrophils of the CMV genetic material by real-time PCR;
* study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum);
* determine the content of CMV specific T-cells in peripheral blood;
* develop a method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent persons and treatment of patients in this category.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with CMV infection
Bood leukocyte subsets
Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
CMV specific T-cells
CMV specific T-cells detected by flow cytometry
serum CMV IgM / IgG antibodies
serum CMV IgM / IgG antibodies detected by ELISA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bood leukocyte subsets
Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
CMV specific T-cells
CMV specific T-cells detected by flow cytometry
serum CMV IgM / IgG antibodies
serum CMV IgM / IgG antibodies detected by ELISA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* fever of not clear etiology
* confirmed CMV infection
Exclusion Criteria
* taking hormones, cytostatics;
* drug addiction
* malignant neoplasms over the past 5 years.
* active viral hepatitis or liver cirrhosis;
* immunosuppressive conditions of any etiology
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belarusian State Medical University
OTHER
The Republican Research and Practical Center for Epidemiology and Microbiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elena Fomina, Dr
Role: PRINCIPAL_INVESTIGATOR
Head of the laboratory, RSPCEM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Republican Research and Practical Center for Epidemiology and Microbiology
Minsk, , Belarus
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRPCEM_CMV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.